Business
Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma
Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma\nResults Were Obtained in A Pre-Clinical Study on RCKMC Cannabis Strains\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, March 11, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, March 11, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has completed a scan of selected RCKMC's cannabis strains. Results obtained have shown that two specific strains have demonstrated higher anti-tumor activity. \n\n \n  \n\n \nThe strains were examined at the company's High Throughput Screening (HTS) facility located in Israel, in which their anti-tumor properties were examined on a wide range of cancers.  Analysis of the scans revealed specific cultivars which have a more significant necrotic effect on Gastric Adenocarcinoma cells.\nThe results will be used to further breed the selected cultivars for specific cancers, focusing on Gastric cancers. The cultivars to be developed will be the source for active pharmaceutical ingredients (API's) for future clinical studies.  \nAbout RCKMC   \nRCK is an Israeli cannabis company, breeding tailor-made medical strains and repeatable & stable cannabis hybrid-seeds, being the first company to operate a methodological marker-assisted-breeding of cannabis, having cutting-edge proprietary technologies and led by professional team, RCKMC opens the gate to a new era of cannabis agriculture.\nFor more information: https://www.rckmc.com\nAbout Cannabics Pharmaceuticals\nCannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S public company that is developing a platform that leverages novel drug-screening tools to create cannabinoid-based therapies for cancer that are more precise to a pati...